NCT04933344

Pharmacokinetics and Toxicodynamics of Daptomycin in Bone and Joint Infections

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 1,130 (estimated)
• Sponsor: Hospices Civils de Lyon · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: —

Summary

the aim of this study is to investigate the relationship between exposure to daptomycin and the occurrence of muscle toxicity or eosinophilic pneumonia in patients treated with daptomycin for bone and joint infection

Detailed description

Daptomycin is widely used in osteoarticular infections (IOA), as an alternative to vancomycin, and recommended for this use by various learned societies including the Infectious Diseases Society of America (IDSA) in 2013. Tolerance to daptomycin is generally favorable, with in particular better renal tolerance than vancomycin. However, two rare and potentially severe side effects have been described with this antibiotics: muscle toxicity and eosinophilic pneumonia.

Conditions

• Dactinomycin Adverse Reaction
• Bone and Joint Infection

Interventions

Type	Name	Description
OTHER	patients having had BJI or PJI treated with daptomycin	patients having had BJI or PJI treated with daptomycin who developped an adverse event : eosinophilic pneumonia and/or elevation of CPK

Timeline

• Start date: 2021-06-15
• Primary completion: 2022-03-01
• Completion: 2022-07-01
• First posted: 2021-06-21
• Last updated: 2022-05-06

Locations

1 site across 1 country: France